Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models
In this study, chTNT-3/CpG retained immunostimulatory activity of the CpG moiety and enabled delivery to tumors. Because systemically administered CpG rapidly clear the body and do not accumulate into tumors, chTNT-3/CpG provide a solution to the limitations observed in preclinical and clinical trials.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Allergy & Immunology | Cancer | Cancer & Oncology | Chemistry | Clinical Trials | Colon Cancer | Colorectal Cancer | Immunotherapy | Melanoma | Skin Cancer | Study